Preclinical Virology In Vitro Testing & Screening
We provide comprehensive in vitro virology services to accelerate your early-stage antiviral drug discovery. Our expert team offers robust, reproducible cell-based screening and customized assay development to evaluate compound efficacy, toxicity, and mechanism of action before you advance to in vivo translational models.
Antiviral Efficacy Assays
In vitro antiviral assays evaluate the potency and efficacy of small molecules, biologics, and novel therapeutic candidates against specific viral pathogens in controlled cell culture systems. These assays are essential for determining drug candidates’ therapeutic windows ( vs. ) early in the discovery pipeline.
Plaque Reduction Assay (PRA)
The gold standard method for direct quantification of infectious viral titers and neutralizing activity.
TCID_50 Assay (50% Tissue Culture Infectious Dose)
Endpoint titration assay used to measure viral infectivity and determine viral stock titers across broad cell lines.
EC_50 / CC_50 Determination
Simultaneous measurement of the half-maximal effective concentration (EC50) and half-maximal cytotoxic concentration (CC50) to establish the Selectivity Index (SI).
Cytopathic Effect (CPE) Inhibition Assay
High-throughput screening method measuring cell viability using colorimetric (MTT/MTS) or luminescence readouts to detect protection against virus-induced cell death.
Viral Quantification & Characterization Assays
Accurate quantification of viral load and functional inhibition is critical for validating candidate compounds across various viral families.
Hemagglutination Inhibition (HI) Assay
Evaluates the ability of therapeutics or antibodies to block viral surface proteins from binding to host cell receptors.
Focus Forming Assay (FFA)
Immunostaining-based plaque variant assay optimized for non-plaque-forming viruses to quantify viral foci rapidly.
Quantitative Real-Time PCR (qPCR / RT-qPCR)
Molecular quantification of viral RNA/DNA copy numbers to assess inhibition of viral replication cycles.
Custom Assay Development & Screening
Plaque Reduction Assay (PRA)
Elucidates the specific stage of the viral replication cycle (entry, replication, or release) targeted by your test article.
Cytotoxicity Profiling
Broad toxicity screening across primary and immortalized cell lines to ensure candidate safety profiles.